Study

Integration of machine learning and genomics to predict outcomes for newly diagnosed, relapsed and refractory mature T-cell and NK-cell neoplasms: a global study of the PETAL Consortium

Overall Survival (OS): Measure how long patients live after treatment. This includes patients who are newly diagnosed, have disease that didn't respond to first treatment (primary refractory), or have their first relapse. Compare results for those treated with a new drug (approved or in a trial) versus standard multi-drug chemotherapy. Time to Next Treatment (TNT): Track how long before patients need another treatment. Focus on patients with newly diagnosed, primary refractory, or first relapse T-cell lymphoma (TCL). Compare new drug treatments (approved or trial) to standard chemotherapy. Stem Cell Transplant: See if patients can move on to stem cell transplant (either donor or their own cells) after treatment. Compare success rates for new drugs versus standard chemotherapy. Molecular Data and Outcomes: Study how genetic details of the lymphoma relate to treatment results. Look at response length, progression-free survival, and overall outcomes. Machine Learning: Use advanced computer models, like synthetic intervention methods, to predict general outcomes and how patients respond to specific treatments.

Why this Research Matters

This study will follow patients with T-cell or NK-cell cancers who are newly diagnosed or whose disease has come back. Patients join during their first visit and are tracked for up to 4 years. Researchers will collect information like age, health details, tumor genetics, scans, treatments, and quality of life. Data will be stored securely and shared among hospitals in the study. Genetic tests, such as sequencing, will be done on tumor samples and other materials like blood and saliva when possible. Advanced computer tools will be used to predict how patients respond to treatment and how long they survive.

Who can Participate

Adult

Inclusion Criteria 1. Adults (18+) with T-cell or NK-cell lymphoma that is untreated, has come back (relapsed), or did not respond to treatment (refractory) can join the study. 2. All types of PTCL are allowed except: - T-cell large granular lymphocytic leukemia - Skin-related T-cell lymphomas (like mycosis fungoides, Sézary syndrome, or CD30+ skin disorders) Exclusion Criteria 1. Patients with: - Precursor T/NK cancers - T-cell large granular lymphocytic leukemia - Skin-related T-cell lymphomas (like mycosis fungoides, Sézary syndrome, or CD30+ skin disorders)